MarketPulse

IBD treatment

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Spyre Therapeutics Prices $403M Stock Offering at $62 Per Share

Spyre Therapeutics prices $403M stock offering at $62/share with 6.5M shares, expected to close April 16, 2026. Prominent underwriters include Goldman Sachs and Jefferies.
SYREpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Spyre Therapeutics Raises $300M in IPO to Fund IBD Drug Development

Clinical-stage biotech Spyre Therapeutics announced $300M public offering with $45M underwriter option, led by Jefferies and Goldman Sachs, targeting IBD treatments.
SYREpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Teva, Blackstone Life Sciences Team Up on $400M Deal for GI Drug duvakitug

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.
SNYTEVAmonoclonal antibodyclinical development